Dacomitinib effectively penetrates GBM tumors, with 14.3% of patients experiencing clinical benefit and 8.9% achieving PFS for at least one year.362 Napabucasin disrupts STAT3 and NF-κB signaling, inhibiting GBM cell proliferation, colony formation, and invasion, while in vivo studies have confirmed its efficacy in impairing GBM growth in xenograft models.363 Infigratinib demonstrates superior efficacy over larotrectinib in GBM patients with tyrosine kinase alterations, despite a greater adverse effect profile. This evidence concerns the gene NFKB1 and glioblastoma.